Loading organizations...
Regado Biosciences is a technology company.
Regado Biosciences was a biotechnology company focused on developing therapeutic aptamers with active control agents. The company’s core product involved a novel platform designed to create highly specific and reversible treatments for various medical conditions, particularly within the cardiovascular system. This approach allowed for precise drug regulation, offering the potential for enhanced safety and efficacy in managing critical diseases affecting both arterial and venous applications.
The company was founded in 2001, with Chris Rusconi notably spearheading its scientific endeavors from inception. Rusconi’s insight centered on the potential of aptamer technology, combined with controllable reversal agents, to address significant unmet needs in therapeutic areas requiring finely tuned drug activity. His pedigree in pharmaceutical science and development drove the foundational research that defined Regado's unique approach to drug design.
Regado Biosciences aimed to serve patients suffering from complex cardiovascular diseases, where current treatments often lacked optimal control or reversibility. The company’s overarching vision was to improve patient outcomes by providing a new generation of therapeutics that allowed clinicians unprecedented command over drug action. This forward-looking approach sought to transform treatment paradigms, enhancing safety and therapeutic benefits in critical care settings.
Regado Biosciences has raised $114.0M across 3 funding rounds.
Regado Biosciences has raised $114.0M in total across 3 funding rounds.
Regado Biosciences has raised $114.0M in total across 3 funding rounds.
Regado Biosciences's investors include RusnanoMedInvest, Domain Associates, Aurora Funds, Baxter Ventures, Caxton Advantage, Quaker Partners.
Regado Biosciences is a clinical-stage biotechnology company that developed two‑component therapeutic systems—an aptamer drug plus a matched active control agent—focused primarily on anticoagulation and cardiovascular indications. This platform aims to deliver potent, reversible antithrombotic therapies that allow physicians to rapidly modulate or halt drug activity when bleeding risk arises[1][5].
High‑level overview
Origin story
Core differentiators
Role in the broader tech/biotech landscape
Quick take & future outlook
Sources: company program descriptions and patent/press reporting on Regado’s two‑component aptamer + control technology, clinical pipeline summaries, and financing/transaction notices (company profiles and press coverage)[1][5][3][2][7].
Regado Biosciences has raised $114.0M across 3 funding rounds. Most recently, it raised $51.0M Series E in December 2012.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2012 | $51.0M Series E | RusnanoMedInvest | Domain Associates, Aurora Funds, Baxter Ventures, Caxton Advantage, Quaker Partners |
| Dec 1, 2009 | $40.0M Series D | Domain Associates, Aurora Funds, Caxton Advantage, Quaker Partners | |
| Mar 1, 2007 | $23.0M Series C | Domain Associates |